|
Apr 29
|
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
|
|
Apr 11
|
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
|
|
Apr 2
|
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
|
|
Apr 1
|
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
|
|
Mar 22
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Q4 2023 X4 Pharmaceuticals Inc Earnings Call
|
|
Mar 21
|
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results
|
|
Mar 21
|
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 12
|
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
|
|
Dec 9
|
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
|
|
Dec 4
|
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 6
|
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Sep 5
|
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
|
|
Jun 30
|
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|